Payment overview · 2025
General Payments
$164,341.71
186 reported records · 14 companies
Healthcare provider profile · identity verified
Alan Jeffrey Rechter, MD
Allopathic & Osteopathic Physicians|Orthopaedic Surgery · HOUSTON, TX · NPI 1497732739
Verified facts
What the public records show
CMS Open Payments records show Alan Jeffrey Rechter, MD received $164,341.71 in general payments during 2025 across 186 reported records.
Heron Therapeutics, Inc. accounted for 82.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Heron Therapeutics, Inc. | Unresolved — no canonical attribution shown | $135,000.23 | 82.2% | 115 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $21,247.12 | 12.9% | 18 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $4,499.31 | 2.7% | 37 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $2,814.50 | 1.7% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $172.91 | 0.1% | 1 | 2025 |
| Next Science LLC | Unresolved — no canonical attribution shown | $145.57 | 0.1% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $144.03 | 0.1% | 1 | 2025 |
| Shoulder Innovations, Inc. | Unresolved — no canonical attribution shown | $84.13 | 0.1% | 1 | 2025 |
| Nalu Medical, Inc. | Unresolved — no canonical attribution shown | $53.47 | 0.0% | 3 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $50.93 | 0.0% | 2 | 2025 |
| TREACE MEDICAL CONCEPTS, INC. | Unresolved — no canonical attribution shown | $49.66 | 0.0% | 2 | 2025 |
| MicroPort Orthopedics Inc | Unresolved — no canonical attribution shown | $32.57 | 0.0% | 1 | 2025 |
| ERMI LLC | Unresolved — no canonical attribution shown | $30.37 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.91 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $127,933.50 | 33 |
| Travel and Lodging | $19,339.34 | 59 |
| Consulting Fee | $11,264.50 | 11 |
| Food and Beverage | $5,804.37 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZYNRELEF Normalized: zynrelef |
Drug | Heron Therapeutics, Inc. | $134,955.03 | 114 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $21,247.12 | 18 | 2025 |
Source payment records
|
|||||
| APONVIE Normalized: aponvie |
Drug | Heron Therapeutics, Inc. | $10,815.99 | 5 | 2025 |
Source payment records
|
|||||
| MAKO Normalized: mako |
Device | Stryker Corporation | $3,435.06 | 19 | 2025 |
Source payment records
|
|||||
| INSIGNIA Normalized: insignia |
Device | Stryker Corporation | $557.94 | 9 | 2025 |
Source payment records
|
|||||
| RESTORATION Normalized: restoration |
Device | Stryker Corporation | $279.16 | 6 | 2025 |
Source payment records
|
|||||
| ANTHEM Normalized: anthem |
Device | Globus Medical, Inc. | $172.91 | 1 | 2025 |
Source payment records
|
|||||
| StelKast Generic Knee instruments Normalized: stelkast generic knee instruments |
Device | Globus Medical, Inc. | $172.91 | 1 | 2025 |
Source payment records
|
|||||
| BlastX Normalized: blastx |
Device | Next Science LLC | $145.57 | 1 | 2025 |
Source payment records
|
|||||
| Xperience Normalized: xperience |
Device | Next Science LLC | $145.57 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVENT Normalized: alphavent |
Device | Stryker Corporation | $145.22 | 1 | 2025 |
Source payment records
|
|||||
| REAL INTELLIGENCE Normalized: real intelligence |
Device | Smith+Nephew, Inc. | $144.03 | 1 | 2025 |
Source payment records
|
|||||
| InSet System Normalized: inset system |
Device | Shoulder Innovations, Inc. | $84.13 | 1 | 2025 |
Source payment records
|
|||||
| SECUR-FIT Normalized: secur fit |
Device | Stryker Corporation | $81.93 | 2 | 2025 |
Source payment records
|
|||||
| Nalu Neurostimulation System Normalized: nalu neurostimulation system |
Device | Nalu Medical, Inc. | $53.47 | 3 | 2025 |
Source payment records
|
|||||
| LAPIPLASTY SYSTEM 1 Normalized: lapiplasty system 1 |
Device | TREACE MEDICAL CONCEPTS, INC. | $34.44 | 1 | 2025 |
Source payment records
|
|||||
| MPO Medial Pivot Knee Normalized: mpo medial pivot knee |
Device | MicroPort Orthopedics Inc | $32.57 | 1 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $32.51 | 1 | 2025 |
Source payment records
|
|||||
| XCELL Normalized: xcell |
Device | Bioventus LLC | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| TMC NANOPLASTY SYSTEM Normalized: tmc nanoplasty system |
Device | TREACE MEDICAL CONCEPTS, INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Meloxicam | Meloxicam | 1716 | 527 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 264 | 149 |
| Celecoxib | Celecoxib | 163 | 46 |
| Cephalexin | Cephalexin | 66 | 57 |
| Tramadol Hcl | Tramadol Hcl | 56 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 29 |
| Nabumetone | Nabumetone | 18 | 11 |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Gabapentin | Gabapentin | 12 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $164,341.71 · 186 records | Heron Therapeutics, Inc. | ALPHAVENT, ANTHEM, APONVIE, BlastX, EVENITY, EXOGEN ULTRASOUND BONE HEALING SYSTEM, INSIGNIA, InSet System, JOURNAVX, LAPIPLASTY SYSTEM 1, MAKO, MPO Medial Pivot Knee, Nalu Neurostimulation System, REAL INTELLIGENCE, RESTORATION, SECUR-FIT, StelKast Generic Knee instruments, TMC NANOPLASTY SYSTEM, XCELL, Xperience, ZYNRELEF | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error